Nicotine effect on P-ERK, COX-2, PGE2 and VEGF expression in oral squamous cancer

Hamraz, Minoo; Salimi, Mona; Esfahani, Masoumeh; Sedaghati, Bita; Aslani, Hamidreza; Bazarchi, Azadeh

doi:10.1016/j.jbiotec.2010.09.631

Cited by 5 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Smoking is another risk factor for gastric cancer, as nicotine is strongly associated with gastric cancer metastasis by increasing IL-8 expression via the activation of ROS/NF-κB and ROS/MAPK (ERK 1/2, p38)/AP-1 axes in AGS gastric cancer cells, which stimulates angiogenesis and endothelial cell proliferation [ 115 ]. Furthermore, nicotine induces epithelial-mesenchymal transition (EMT) and stimulates the cyclooxygenase-2 (COX-2)/prostaglandin E2 (PGE2) signaling pathway and expression of endothelial nitric oxide synthase (eNOS) in different cancer cells [ 116 , 117 , 118 ]. A meta-analysis study reported that alcohol consumption can also increase the risk of gastric cancer [ 119 ].…”

Section: Gastric Cancermentioning

confidence: 99%

Anti-Oxidant and Anti-Inflammatory Effects of Astaxanthin on Gastrointestinal Diseases

Lee

Kim

2022

IJMS

View full text Add to dashboard Cite

A moderate amount of reactive oxygen species (ROS) is produced under normal conditions, where they play an important role in cell signaling and are involved in many aspects of the immune response to pathogens. On the other hand, the excessive production of ROS destructs macromolecules, cell membranes, and DNA, and activates pro-inflammatory signaling pathways, which may lead to various pathologic conditions. Gastrointestinal (GI) mucosa is constantly exposed to ROS due to the presence of bacteria and other infectious pathogens in food, as well as alcohol consumption, smoking, and the use of non-steroidal anti-inflammatory drugs (NSAID). Prolonged excessive oxidative stress and inflammation are two major risk factors for GI disorders such as ulcers and cancers. Bioactive food compounds with potent anti-oxidant and anti-inflammatory activity have been tested in experimental GI disease models to evaluate their therapeutic potential. Astaxanthin (AST) is a fat-soluble xanthophyll carotenoid that is naturally present in algae, yeast, salmon, shrimp, and krill. It has been shown that AST exhibits protective effects against GI diseases via multiple mechanisms. Residing at the surface and inside of cell membranes, AST directly neutralizes ROS and lipid peroxyl radicals, enhances the activity of anti-oxidant enzymes, and suppresses pro-inflammatory transcription factors and cytokines. In addition, AST has been shown to inhibit cancer cell growth and metastasis via modulating cell proliferation-related pathways, apoptosis, and autophagy. Considering the potential benefits of AST in GI diseases, this review paper aims to summarize recent advances in AST research, focusing on its anti-oxidant and anti-inflammatory effects against gastric and intestinal ulcers and cancers.

show abstract

Section: Gastric Cancermentioning

confidence: 99%

Anti-Oxidant and Anti-Inflammatory Effects of Astaxanthin on Gastrointestinal Diseases

Lee

Kim

2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Its consumption through an NRT product orally may place a patient at risk of oral neoplastic changes. [69][70][71][72][73] There is limited research of NRT links to oral malignancy and impacts in conjunction with head-and-neck radiotherapy.…”

Section: Adverse Effects Of Nicotine Replacement Therapy On Oral Healthmentioning

confidence: 99%

Oral health and nicotine replacement therapy product

Manakil

Miliankos

Gray

et al. 2020

European Journal of General Dentistry

View full text Add to dashboard Cite

Tobacco-related addiction has huge financial implications, not only for the users but also for the public. [1,2] While rates of smoking are declining in 2015, 11.5% of global deaths were attributable to smoking worldwide. [3] A key objective of the Government and all health professionals is to eliminate or to reduce the impact of tobacco usage on the wider population. Current knowledge about tobacco use and its effects has led to the understanding that there is no safe way to use tobacco and that total cessation is imperative to avoid any number of debilitating and eventually fatal conditions. [4] Various methods of achieving cessation have been proposed, including behavioral counseling and pharmacotherapy. The paradigm for cessation has changed over the years with a shift toward viewing addiction as a disease and the contemporary approach toward the management of tobacco addiction centers around a combination of education, counseling, and pharmacotherapy. [5] A method of assisting users in achieving cessation goals has been through the substitution of pure nicotine with tobacco-less products. [6] Nicotine replacement products (NRPs) are the collective name for a range of over-the-counter medications containing pure nicotine, designed to aid users of tobacco products in reducing their intake of such products, or to achieve a total cessation of use. [1,7,8] This pathway reduces the withdrawal symptoms associated with a reduction of intake or total cessation. [1,7,8] The use of nicotine substitution through one or more NRPs to aid cessation of tobacco use is termed as nicotine replacement therapy (NRT), and in the contemporary setting is considered as first-line therapy for smoking cessation.NRT products are available in many different forms for consumers, including chewing gums, [9] lozenges or mints, [10] inhalers, [11] patches, [12] and vaporizers (also called E-cigarettes or Electronic cigarettes). [13] Nicotine drinks, straws, and lollipops are other developed and marketed products. [14] These products are available in varying strengths of nicotine based on the tobacco user's habitual intake or "stage of quitting." Except for nicotine patches (where nicotine is absorbed transdermally) and nasal sprays (where nicotine is absorbed through nasal mucosa), all other forms of NRP deliver nicotine

show abstract

Section: Adverse Effects Of Nicotine Replacement Therapy On Oral Healthmentioning

confidence: 99%

Untitled

2020

European Journal of General Dentistry

View full text Add to dashboard Cite

Nicotine effect on P-ERK, COX-2, PGE2 and VEGF expression in oral squamous cancer

Cited by 5 publications

References 0 publications

Anti-Oxidant and Anti-Inflammatory Effects of Astaxanthin on Gastrointestinal Diseases

Anti-Oxidant and Anti-Inflammatory Effects of Astaxanthin on Gastrointestinal Diseases

Oral health and nicotine replacement therapy product

Untitled

Contact Info

Product

Resources

About